Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Interventional × SLC-0111 × Clear all

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Metastatic Pancreatic Ductal Adenocarcinoma 1

Interventions

Cyclophosphamide 1820 Radiotherapy 1675 Cisplatin 1597 Carboplatin 1359 Gemcitabine 1265 Paclitaxel 1157 Bevacizumab 1121 Docetaxel 1084 pembrolizumab 1063 Oxaliplatin 1037 Capecitabine 1027 Fluorouracil 967 Dexamethasone 871 Rituximab 827 Nivolumab 812 Magnetic Resonance Spectroscopy 767 Doxorubicin 742 Etoposide 741 Irinotecan 701 Drug Therapy 686 Radiosurgery 685 Cytarabine 656 fludarabine 632 Leucovorin 616 Lenalidomide 549 fludarabine phosphate 505 Temozolomide 493 Radiation 489 Filgrastim 482 Cetuximab 473

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03450018 2024-05-24

SLC-0111-17-01

British Columbia Cancer Agency

Phase 1/2 Terminated

Gastrointestinal

Metastatic Pancreatic Ductal Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡